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Purpose: The molecular markers cluster of differentiation (CD)24, CD44, adenosine tri-phosphate (ATP) binding cassette
protein G2 (ABCG2), and epithelial cell adhesion molecule (EpCAM) are widely used, individually or in combination,
to characterize some types of cancer stem cells. In this study we characterized the EpCAM+ retinoblastoma (RB) cells for
their cancer stem-like properties in vitro. Additionally, we targeted RB tumor cells via redirecting T cells using bispecific
EpCAM×CD3 antibody.
Methods: Flow cytometry was used to study the co-expression of EpCAM with putative cancer stem cell markers, such
as CD44, CD24, and ABCG2, in RB primary tumors. In vitro methyl thiazol tetrazolium (MTT) assay, invasion assay,
and neurosphere formation assay were performed to characterize EpCAM+ cells for their cancer stem/progenitor cell-like
properties. We assessed the in vitro efficacy of bispecific EpCAM×CD3 antibody on RB tumor cell proliferation and
validated the results by evaluating effector cytokine production in the culture medium with the ELISA method.
Results: EpCAM was co-expressed with all cancer stem cell markers (CD44, CD24, and ABCG2) in primary RB tumors.
EpCAM+ cells showed significantly higher proliferative invasive potential and neurosphere formation in vitro compared
to EpCAM– Y79 cells. EpCAM+ cells showed higher β-catenin expression compared to EpCAMˉ cells. EpCAM×CD3
significantly retarded proliferation of RB primary tumor cells. EpCAM×CD3 effectively induced the secretion of effector
cytokines, such as interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-10, IL-2, and transforming growth
factor (TGF)-β1, and also perforin levels by pre-activated lymphocytes.
Conclusions: EpCAM might be a novel cancer stem cell marker in RB. EpCAM×CD3 antibody redirecting T cells to
attack RB tumor cells may prove effective in RB management. Further preclinical studies are needed to confirm the initial
findings of our study.
Retinoblastomas  (RBs),  although  rare,  are  the  most
frequent  primary  eye  malignancy  diagnosed  in  children.
Retinoblastomas  commonly  invade  through  the  sclera  or
along the optic nerve or hematogenously via the choroid.
Distant  metastasis  is  uncommon  after  early  surgery  and
chemotherapy, and the 5-year survival rate is approximately
90%.  Without  treatment,  retinoblastomas  are  almost
universally fatal.
Presence of cancer stem cells in solid tumors have been
shown to have a bad prognosis associated with drug resistance
[1]. The existence of cancer stem-like cells has been reported
in various malignancies, such as acute leukemia [2-4] and
neural [5], breast [6,7], and ovarian tumors [8]. Previously,
we reported that ATP binding cassette protein G2 (ABCG2)
and mini chromosome maintenance protein 2 (MCM2) cancer
stem cell (CSC)-like markers are expressed in retinoblastoma
tumors [9], and recent reports have demonstrated that stem
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cells  expressing  Oct4,  Nanog,  ALDH1,  and  low  Hoechst
33342 cells are present in human RB cells [10,11]. Epithelial
cell adhesion molecule (EpCAM), an epithelial cell adhesion
molecule earlier identified as a marker for stem/progenitor
cells of adult liver and oval cells [12,13], seems to present all
the characteristics of CSCs. Earlier; our group showed that
EpCAM  is  highly  expressed  in  RB  tumors  with  invasion
compared to tumors without invasion [14]. Subsequently, we
demonstrated that impairment of the EpCAM gene leads to a
marked decrease in cell proliferation [15]. However, there is
no evidence as to whether EpCAM protein contributes to
cancer stemness of RB tumor cells. In the present study we
characterized the EpCAM+ cells for their cancer stem cell
properties in vitro and evaluated EpCAM co-expression with
cancer stem cell-like markers, such as cluster determinant
(CD)44, CD24, and ABCG2, in fresh primary retinoblastoma
tumors.
Bispecific antibodies (bsAb) are artificial molecules with
dual specificity to two different antigens. The most commonly
used antigen for bsAb on lymphocytes is an invariant CD3
signaling  complex,  which  induces  polyclonal  T-cell
activation. Several bsAb and single-chain antibody constructs
against  EpCAM  have  been  generated  and  tested  as
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290immunotherapeutic agents [16-21]. Host antitumor immunity
has been considered to play a role in protection against the
development  of  malignancy.  However,  host  mononuclear
cells  may  become  dysfunctional  when  there  is  a  lack  of
expression  of  tumor-associated  antigens  or  various  co-
stimulatory or major histocompatibility complex molecules in
the tumor cells. Earlier we demonstrated that aggressive RB
primary  tumors  express  low  levels  of  human  leukocyte
antigen (HLA) class I and class II antigens, which could be an
advantage for tumor cells to escape from T-cell- or natural
killer (NK) cell-mediated attack [22]. In this context, a novel
therapeutic  strategy  that  uses  a  bispecific  antibody  that
redirects T cells to attack tumor cells could be an attractive
treatment  modality  in  retinoblastoma  management.  The
bispecific antibody that we used has been shown to efficiently
induce tumor cell lysis in vitro and reduce malignant ascites
production in advanced ovarian cancer patients [23,24]. In the
present study, besides demonstrating EpCAM as a cancer
stem cell marker, we investigated the antitumor efficacy of
EpCAM×CD3 bispecific antibody in retinoblastoma primary
tumors.
METHODS
Tissue  collection:  All  samples  were  collected  with  the
approval of the institutional review board at Vision Research
Foundation (VRF) and in accordance with the Declaration of
Helsinki. The retinoblastoma tumor samples were collected
from the eyes enucleated from the retinoblastoma patients.
When a patient is advised for enucleation as part of therapy,
the eyeball will be sent to Department of Ocular Pathology for
diagnostic  purpose.  According  to  the  institutional  ethics
committee policies, a general consent is taken from all the
patients who undergo enucleation. The age range and gender
of all the patient samples included in this study is mentioned
in the Table 1.Whatever clinicopathological parameters are
required for marker correlations have been mentioned in the
Table 1. Fresh unfixed eyeballs of patients with diagnosed RB,
without any prior treatment, were included in the study. The
enucleated eyeballs were obtained in sterile condition. After
the fresh tissue was placed in plain RPMI medium, singly
suspended cells were analyzed by flow cytometry. The slides
were reviewed by an experienced ocular pathologist (S.K.)
specifically  for  features  of  differentiation;  histologic  risk
factors, such as involvement of optic nerve, choroid, anterior
segment; and other associated features. The clinical profiles
of the patients were obtained from their medical records.
Flow cytometry: Single cell suspensions were prepared from
tissues by mechanical disruption using syringe coupled with
an 18G needle. Cells (2×105 in each reaction) were suspended
in 50 ml of fuorescence-activated cell sorting (FACS) buffer
(0.5% BSA (BSA) and 0.02% sodium azide in phosphate
buffer solution (PBS); 137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4, 1.47 mM KH2PO4; pH adjusted to 7.4; Sigma-
Aldrich, Saint Louis, MO) and blocked with FcR blocking
reagent  (2  µl/2×105  cells;  Miltenyi  Biotech,  Gladbach,
Germany) for 15 min at 4 °C. Initially cell viability was tested
using  propidium  iodide  (PI)  viability  staining  solution
(eBioscience, San Diego, CA). Viable cells were defined by
their forward scatter cell/side scatter cell (FSC/SSC) profiles
and in addition, their lack of PI. Cells were then incubated for
45 min with a primary antibody for EpCAM, CD24, CD44,
and  ABCG2.  Isotype  controls  for  the  corresponding
antibodies  used  were  as  follows:  antigen  presenting  cell
(APC)-conjugated mouse IgG2a κ-isotype control (50 µg/
0.5  ml),  photoelectric  (PE)-conjugated  rat  IgG2b  isotype
control  (0.2  mg/ml),  fluorescein  isothiocyanate  (FITC)-
conjugated mouse IgG1 κ-isotype control (0.2 mg/ml), FITC-
conjugated antimouse IgG1 (0.5 mg/ml; eBioscience, San
Diego,  CA).  The  antibodies  used  were  mouse  FITC-
conjugated antihuman EpCAM (B29.1; 0.1 mg/ml; Abcam,
Figure 1. Elimination of dead cell population from the final analysis.A: Scatter plot showing most cells with small size and high granularity,
which represent dead cells; hence the dead were eliminated from the final analysis. B: Plot showing 58% of the cells stained for PI were
eliminated from the final analysis as the PI positive cells represent dead cell population. C: Gated scatter plot shows control cells without PI
stain.
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292Cambridge,  UK),  mouse  PE-conjugated  antihuman  CD44
(F10, 0.1 mg/ml; Abcam), mouse APC-conjugated antihuman
CD24  (ML5,  25  µg/ml;  Biolegend,  San  Diego,  CA),  and
mouse FITC-conjugated antihuman ABCG2 (CD3, 25 µg/ml;
Biolegend).
Cells  were  washed  with  FACS  buffer  after  antibody
incubation and were analyzed with flow cytometry (CellQuest
software; BD Biosciences, San Jose, CA) on a customized
system (BD-FACS Calibur; BD Biosciences).
Elimination of dead cells from the analysis: The RB tumor
tissues included dead cells (ranging from 25.2%±2.3% to
75.1%±1.2%), which were characterized by their small size,
high  granularity,  and  positivity  for  PI  dye.  These  were
eliminated  from  the  final  analysis  by  appropriate  gating
(Figure 1A-C). Subsequently, the samples were evaluated for
dead cells and marker expression in viable cells.
Isolation of EpCAM+ cells from Y79 cell line: EpCAM+ cells
were isolated from the Y79 cell line using CELLection Pan
Mouse IgG kit (Invitrogen, Bangalore, India), according to the
manufacturer’s  instructions.  Briefly,  Dynabeads  were
incubated with EpCAM primary monoclonal antibody (Santa
Cruz  Biotechnology,  Santa  Cruz,  CA)  overnight,  and  the
beads were then washed with 1% BSA in PBS (pH 7.4) to
remove free unbound antibody. Approximately 3×106 Y79
cells were then incubated with beads at 4 °C for 30 min on a
tube rotator. After incubation, bead-bound cells were washed
thrice with 1% BSA in PBS (pH 7.4) using a magnetic stand.
The  washed  cells  were  resuspended  in  buffer  containing
RPMI 1640 and 1% fetal calf serum (FCS), 1 mM CaCl2, and
4 mM MgCl2 (pH 7.0–7.4). The cells were detached from the
magnetic  beads  using  releasing  buffer  (DNase  1)  by
incubating the cells at room temperature for 15 min. The
released cells in the supernatant were collected carefully using
magnetic beads for downstream applications.
EpCAM siRNA transfection: After  sorting out the EpCAM+
Y79 cells from the parental cell line, EpCAM-specific small
interfering  RNA  (siRNA)  treatment  was  performed  as
described in our previous report [15].
Briefly, for each well of cells, 200 nm of siRNA and 12 µl
of Hi-perfect transfection reagent was mixed with 88 µl of
serum free RPMI medium in a vial and incubated for 5–10
min  at  room  temperature  (RT)  to  allow  the  transfection
complex formation. Then the complex was added drop-wise
to the wells containing Y79 cells and the plate was gently
swirled to ensure the uniform distribution of the transfection
complex. The plates were incubated further for 6 h in a CO2
incubator at 37 °C. After 4 h of incubation, 400 µl of complete
RPMI medium was added to the wells and incubated further
for 24–72 h. Briefly, 1x105 cells were plated in each well of
six-well plates and allowed to grow for 24–36 h (until they
were 40%–60% confluent). Small interefering RNA (siRNA)
was then transfected into cells at a concentration of 200 nM
using Hi-Perfect transfection reagent (Qiagen, Santa Clara,
CA) and serum-free medium. After 4 h of incubation, serum-
rich  medium  was  added.  Human  EpCAM  siRNA
(Hs_TACSTD1_10; catalog number SI04343416; Forward
strand: GGA ACU CAA UGC AUA ACU Att and the reverse
strand: UAG UUA UGC AUU GAG UUC Cct) and scrambled
siRNA (catalog number 1022563) were used in this study.
In vitro cell proliferation assay: For the evaluation of the cell
proliferation rate, cells were seeded on 96-well plates at a
density  of  1×104  cells/well  in  complete  RPMI  medium,
followed by the methyl thiazol tetrazolium assay (MTT assay;
Sigma-Aldrich). The amount of MTT formazan produced was
determined using a microplate reader and an absorbance of
560 nm (Beckman Coulter India Private Ltd, New Delhi,
India)
Figure 2. Percentage positivity of putative cancer stem cell markers in primary retinoblastoma (RB) tumors. A: Representative scatter plot
shows 61.24% of epithelial cell adhesion molecule (EpCAM) positive cells in the RB tumor. B: Representative scatter plot shows 63.67% of
cluster determinant (CD)44 positive cells in the RB tumors. C: Representative scatter plot shows 63.67% of CD24 positive cells in the RB
tumors. D: Representative scatter plot shows 1.5% of ATP binding cassette protein G2 (ABCG2) positive cells in the RB tumors. EpCAM-
FITC represents EpCAM+ cells identified using fluorescein isothiocyanate (FITC) labeled antibody. CD44-PE represents CD44 positive cells
identified using phycoerythrin labeled antibody. CD24-APC represents CD24 positive cells identified using allophycocyanin labeled antibody.
ABCG2-FITC represents ABCG2 positive cells identified using FITC labeled antibody.
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293Figure  3.  Investigation  of  the  co-expression  of  epithelial  cell
adhesion  molecule  (EpCAM)  with  cluster  determinant  (CD)44,
CD24 and ATP binding cassette protein G2 (ABCG2) markers in
retinoblastoma  (RB)  tumor  1.  A:  Scatter  plot  shows  the  co-
expression of EpCAM with CD44 B: Scatter plot shows the co-
expression of EpCAM with CD24. C: Scatter plot shows the co-
expression  of  EpCAM  with  ABCG2.  EpCAM-fluorescein
isothiocyanate  (FITC)  represents  EpCAM+  cells  identified  using
FITC labeled antibody. CD44-PE represents CD44 positive cells
identified  using  phycoerythrin  labeled  antibody.  CD24-APC
represents  CD24  positive  cells  identified  using  allophycocyanin
labeled antibody. ABCG2-APC represents ABCG2 positive cells
identified using allophycocyanin labeled antibody.
Figure  4.  Investigation  of  the  co-expression  of  epithelial  cell
adhesion  molecule  (EpCAM)  with  cluster  determinant  (CD)44,
CD24 and ATP binding cassette protein G2 (ABCG2) markers in
retinoblastoma  (RB)  tumor  2.  A:  Scatter  plot  shows  the  co-
expression of EpCAM with CD44. B: Scatter plot shows the co-
expression of EpCAM with CD24. C: Scatter plot shows the co-
expression  of  EpCAM  with  ABCG2.  EpCAM-fluorescein
isothiocyanate  (FITC)  represents  EpCAM+  cells  identified  using
FITC labeled antibody. CD44-PE represents CD44 positive cells
identified  using  phycoerythrin  labeled  antibody.  CD24-APC
represents  CD24  positive  cells  identified  using  allophycocyanin
labeled antibody. ABCG2-APC represents ABCG2 positive cells
identified using allophycocyanin labeled antibody.
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294Figure  5.  Investigation  of  the  co-expression  of  epithelial  cell
adhesion  molecule  (EpCAM)  with  cluster  determinant  (CD)44,
CD24 and ATP binding cassette protein G2 (ABCG2) markers in
retinoblastoma  (RB)  tumor  3.  A:  Scatter  plot  shows  the  co-
expression  of  EpCAM  with  Cluster  determinant-44  (CD44).  B:
Scatter plot shows the co-expression of EpCAM with CD24. C:
Scatter  plot  shows  the  co-expression  of  EpCAM  with  ABCG2.
EpCAM-fluorescein  isothiocyanate  (FITC)  represents  EpCAM
positive  cells  identified  using  FITC  labeled  antibody.  CD44-PE
represents CD44 positive cells identified using phycoerythrin labeled
antibody. CD24-APC represents CD24 positive cells identified using
allophycocyanin labeled antibody. ABCG2-APC represents ABCG2
positive cells identified using allophycocyanin labeled antibody.
Figure  6.  Investigation  of  the  co-expression  of  epithelial  cell
adhesion  molecule  (EpCAM)  with  cluster  determinant  (CD)44,
CD24 and ATP binding cassette protein G2 (ABCG2) markers in
retinoblastoma  (RB)  tumor  4.  A:  Scatter  plot  shows  the  co-
expression of EpCAM with CD44. B: Scatter plot shows the co-
expression of EpCAM with CD24. C: Scatter plot shows the co-
expression  of  EpCAM  with  ABCG2.  EpCAM-fluorescein
isothiocyanate (FITC) represents EpCAM positive cells identified
using FITC labeled antibody. CD44-PE represents CD44 positive
cells identified using phycoerythrin labeled antibody. CD24-APC
represents  CD24  positive  cells  identified  using  allophycocyanin
labeled antibody. ABCG2-APC represents ABCG2 positive cells
identified using allophycocyanin labeled antibody..
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295Figure  7.  Investigation  of  the  co-expression  of  epithelial  cell
adhesion  molecule  (EpCAM)  with  cluster  determinant  (CD)44,
CD24 and ATP binding cassette protein G2 (ABCG2) markers in
retinoblastoma  (RB)  tumor  5.  A:  Scatter  plot  shows  the  co-
expression of EpCAM with CD44. B: Scatter plot shows the co-
expression of EpCAM with CD24. C: Scatter plot shows the co-
expression  of  EpCAM  with  ABCG2.  EpCAM-fluorescein
isothiocyanate (FITC) represents EpCAM positive cells identified
using FITC labeled antibody. CD44-PE represents CD44 positive
cells identified using phycoerythrin labeled antibody. CD24-APC
represents  CD24  positive  cells  identified  using  allophycocyanin
labeled antibody. ABCG2-APC represents ABCG2 positive cells
identified using allophycocyanin labeled antibody.
Figure  8.  Investigation  of  the  co-expression  of  epithelial  cell
adhesion  molecule  (EpCAM)  with  cluster  determinant  (CD)44,
CD24 and ATP binding cassette protein G2 (ABCG2) markers in
retinoblastoma  (RB)  tumor  6.  A:  Scatter  plot  shows  the  co-
expression of EpCAM with CD44. B: Scatter plot shows the co-
expression of EpCAM with CD24. C: Scatter plot shows the co-
expression  of  EpCAM  with  ABCG2.  EpCAM-fluorescein
isothiocyanate (FITC) represents EpCAM positive cells identified
using FITC labeled antibody. CD44-PE represents CD44 positive
cells identified using phycoerythrin labeled antibody. CD24-APC
represents  CD24  positive  cells  identified  using  allophycocyanin
labeled antibody. ABCG2-APC represents ABCG2 positive cells
identified using allophycocyanin labeled antibody.
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296Figure  9.  Investigation  of  the  co-expression  of  epithelial  cell
adhesion  molecule  (EpCAM)  with  cluster  determinant  (CD)44,
CD24 and ATP binding cassette protein G2 (ABCG2) markers in
retinoblastoma  (RB)  tumor  7.  A:  Scatter  plot  shows  the  co-
expression of EpCAM with CD44. B: Scatter plot shows the co-
expression of EpCAM with CD24. C: Scatter plot shows the co-
expression  of  EpCAM  with  ABCG2.  EpCAM-fluorescein
isothiocyanate (FITC) represents EpCAM positive cells identified
using FITC labeled antibody. CD44-PE represents CD44 positive
cells identified using phycoerythrin labeled antibody. CD24-APC
represents  CD24  positive  cells  identified  using  allophycocyanin
labeled antibody. ABCG2-APC represents ABCG2 positive cells
identified using allophycocyanin labeled antibody.
Figure  10.  Investigation  of  the  co-expression  of  epithelial  cell
adhesion  molecule  (EpCAM)  with  cluster  determinant  (CD)44,
CD24 and ATP binding cassette protein G2 (ABCG2) markers in
retinoblastoma  (RB)  tumor  8.  A:  Scatter  plot  shows  the  co-
expression of EpCAM with CD44. B: Scatter plot shows the co-
expression of EpCAM with CD24. C: Scatter plot shows the co-
expression  of  EpCAM  with  ABCG2.  EpCAM-fluorescein
isothiocyanate  (FITC)  represents  EpCAM+  cells  identified  using
FITC labeled antibody. CD44-PE represents CD44 positive cells
identified  using  phycoerythrin  labeled  antibody.  CD24-APC
represents  CD24  positive  cells  identified  using  allophycocyanin
labeled antibody. ABCG2-APC represents ABCG2 positive cells
identified using allophycocyanin labeled antibody.
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297In  vitro  cell  invasion  analysis:  We  used  a  24-well  plate
Transwell system with a polycarbonate filter membrane of 8-
mm  pore  size  (Corning,  UK).  The  cell  suspensions  were
seeded to the upper compartment of the Transwell chamber at
a cell density of 1×105 in 100 µl serum-free medium. After 24
h, the medium was removed and the filter membrane was fixed
with 4% formalin for 1 h. The opposite surface of the filter
membrane that faced the lower chamber was stained with
methylene blue for 3 min, and the migrated cells were then
visualized under an inverted microscope.
Y79 cell neurospheres and differentiation assay: EpCAM+/
EpCAMˉ/EpCAMˉsiRNA Y79 cells were plated in a 96-well
dish at densities from 1,000 cells per well to 50 cells per well.
The cells were plated at a low density (50 cells per well) to
prevent the probability of the cells encountering one another
in the well. After 5 days, neurospheres in the wells were
counted and then dissociated into single-cell suspensions and
replated. For the differentiation study, the sorted EpCAM+
(5,000 cells) and EpCAMˉ cells (5,000 cells) were cultured
separately in complete RPMI medium for 2 weeks. After 14
days, the wells containing the EpCAM+ and EpCAMˉ cells
were subjected to flow cytometry analysis to determine the
percentage of EpCAM expression in both populations.
Western blotting: Cells were lysed in RIPA lysis buffer for 15
min on ice. An aliquot (50 µg) of lysate was electrophoresed
by  10%  SDS-polyacrylamide  gel  and  blotted  onto  a
nitrocellulose membrane. Membranes were blocked in 5% fat-
free milk and then incubated separately with 1:500 diluted
mouse monoclonal primary antibody against EpCAM (C-10;
Santa  Cruz  Biotechnology),  EpCAM  and  β-catenin  (E-5,
200 µg/ml; Santa Cruz Biotechnology) overnight at 4 °C. β-
actin was used as the loading control (dilution 1:4,000, AC-15;
Sigma Aldrich). After washing, membranes were incubated
with  horseradish  peroxidase-conjugated  antimouse  IgG
antibody (diluted to 1:2,000; Santa Cruz Biotechnology) for
1 h at room temperature. The bands were visualized using an
enhanced  chemiluminescence  kit  (Amersham,  Pittsburgh,
PA). Each experiment was performed in triplicate.
Effector  and  target  cell  preparation:  Primary  RB  cells
isolated from RB-grossed eyeballs were grown in RPMI (Life
Technologies, Karlsruhe, Germany) supplemented with 10%
FCS (Life Technologies) at 37 °C in a 10% CO2-humidified
incubator. Subconfluent cultures were harvested and checked
for vitality by trypan blue exclusion. Only tumor cells with
viability >95% were used for in vitro cytotoxicity assays.
Peripheral  blood  mononuclear  cells  (PBMC)  of  healthy
donors were used as effector cells for in vitro efficacy analysis
Figure  11.  Determining  the  purity  of
epithelial  cell  adhesion  molecule
(EpCAM)+ cells in the magnetic bead
isolation  process.A:  Scatter  plots
showing unstained cells for EpCAM as
control. B: Scatter plot shows EpCAM
expression in the native Y79 cells before
subjecting  to  magnetic  bead  isolation
assay. C: Scatter plot shows the EpCAM
expression in the Y79 cells that were not
bound to the magnetic beads.D: Scatter
plot shows EpCAM expression in the
Y79  cells  sorted  using  EpCAM
antibody coupled to magnetic beads.
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298of  the  bscEpCAM×CD3  antibody.  PBMCs  were  prepared
using  vacutainers  (BD  Biosciences)  from  fresh  blood
collected from donors at the VRF laboratory. Purified PBMCs
were cultured in RPMI/10% FCS and 25 mmol/l HEPES
(Sigma-Aldrich) and activated with anti-CD3 antibody and
recombinant  IL-2.  The  relative  numbers  of  different
lymphocyte subpopulations (CD3-, CD4-, and CD8-positive
lymphocytes)  were  determined  by  FACS  analysis  using
specific monoclonal FITC-conjugated antibodies as described
in the flow cytometry section.
Activation  of  cytotoxic  lymphocytes:  To  obtain  activated
PBMCs, density gradient purified cells were cultured at a
concentration of 2×106 cells/ml in medium containing OKT3
(5  µg/ml)  and  recombinant  human  IL-2  (20  units/ml;
eBiosciences,  San  Diego,  CA).  After  4  days,  cells  were
washed twice to remove remaining antibodies and cultured
overnight in medium alone. On day 5, a cytotoxicity assay was
performed.
In vitro cytotoxicity assay: Bioactivity of bscEpCAM×CD3
was analyzed by a FACS-based in vitro cytotoxicity assay
using RB tumor cells as target cells and human PBMCs (CD3-
enriched) as effector cells. Target cells were washed twice
with PBS and labeled with 1 μM of CM-DiI reagent RPMI
medium at 37 °C for 5 min and then for additional 15 min at
4 °C. Labeled target cells were washed twice with RPMI/10%
FCS  and  mixed  with  freshly  isolated  effector  cells  at  an
effector-to-target ratio of 10:1 or 5:1. Target (2×105) and
effector cells (1×106 to 2×106) in a volume of 50 µl RPMI/
10% FCS were added per well in a 96-well round-bottomed
plate.  Serial  dilutions  of  bscEpCAM×CD3  (fivefold  or
fourfold) were prepared in RPMI/10% FCS starting with a
concentration of 1 pg/ml. Fifty microliters of the different
bscEpCAM×CD3 solutions were added in triplicate to the
corresponding wells.
Individual cytotoxicity mixtures were incubated for 0, 2,
8, 16, and 24 h at 37 °C/5% CO2. PI was added to a final
concentration of 1 µg/ml per well, and plates were incubated
for 10 min at room temperature. The number of CM-DiI and
PI-positive  target  cells  was  determined  by  FACS.
Cytotoxicity was measured as the ratio of PI-positive cells
(dead  cells)  over  total  number  of  target  cells  (CM-DiI-
positive)  according  to  the  formula  cytotoxicity  (%)=[(PI-
positive cells/CM-DiI-positive cells) × 100]. Dose–response
killing  curves  were  analyzed,  and  the  bscEp-CAM×CD3
concentration that induced half maximal killing (EC50 value)
was calculated.
Enzyme-linked  immunosorbent  assay:  Target  (2×105)  and
effector  cells  (1×106  to  2×106)  were  incubated  with
EpCAM×CD3 or control EpCAM/CD3 antibodies (each at
1 µg/ml) for 72 h, and supernatants were harvested and kept
frozen  −80  °C  until  used.  The  production  of  tumoricidal
cytokines, such as interferon-γ (IFN-γ), tumor necrosis factor-
Figure  12.  Demonstration  of
differentiation  potential  of  epithelial
cell adhesion molecule (EpCAM)+ cells.
A:  Scatter  plot  shows  EpCAM
expression  in  sorted  EpCAM+
population  at  1st  day  of  culture.  B:
Scatter plot shows EpCAM expression
in  sorted  EpCAM+  population  at  day
14th  day  of  culture.  C:  Scatter  plot
shows EpCAM expression in unsorted
EpCAM-  population  at  1st  day  of
culture. D: Scatter plot shows EpCAM
expression  in  sorted  EpCAM+
population at 14th day of culture.
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299α (TNF-α), interleukin-2 (IL-2), IL-10, transforming growth
factor-β1  (TGF-β1),  and  perforin  by  effector  cells  was
measured by the ELISA method. Briefly, pre-coated ready-
set-go ELISA plates were used to measure the cytokines. The
supernatants were added to the wells in triplicates along with
standards provided in separate wells and incubated at room
temperature for 2 h followed by the incubation with detection
antibody for 1 h at RT. After incubation, the solution was
aspirated from the wells and incubated with Avidin-HRP for
30 min at RT. The plate was washed with wash buffer and
incubated with TMB substrate solution for 15 min at room
temperature.  The  plate  was  read  at  450  nm.  Color  was
developed  with  3,  3′,5,5′  tetramethylbenzidine  stabilized
substrate (eBiosciences), stopped by adding 1 N H2SO4; OD
at 450 nm was analyzed using an ELISA plate reader.
Statistical analysis: All the experiments were performed in
triplicate and the results presented as mean±SD. Statistical
analysis was performed using the Student t test wherever
appropriate. A p value <0.05 was considered to be statistically
significant.
RESULTS
Clinical profile: The clinical features of the eight cases are
summarized in Table 1. The mean age of patients included in
the  study  was  29.5±21.8  months  (range  5  to  72  months)
comprising  six  boys  and  two  girls.  All  the  tumors  were
sporadic cases, with right eye involvement in seven cases and
left eye involvement in one case.
Histologic examination: A summary of clinical and histologic
findings is provided in Table 1. There were seven tumors
associated with mild to severe invasion risk factors and one
tumor without invasion. Among tumors with invasion, there
were two tumors with diffuse choroidal invasion, two tumors
with post-laminar optic nerve invasion, three tumors with
focal choroidal invasion, and four tumors with pre-laminar
optic  nerve  invasion.  There  were  four  tumors  with  poor
differentiation, two tumors with moderate differentiation, and
two tumors that were well differentiated.
Phenotypic  analysis  of  tumor  cells:  We  investigated  the
expression  of  four  markers  that  have  previously  been
described for isolation of several types of human CSCs in
human cancer cell lines: CD44, CD24, ABCG2, and EpCAM
[25-32]. In this study CD44, CD24, ABCG2, and EpCAM
could be detected by flow cytometry in all the RB patient
tumor samples. The individual expression of CD44, CD24,
ABCG2, and EpCAM in primary tumor samples ranged from
19% to 64%, 15% to 77%, 2% to 7%, 4% to 65%, respectively
(Figure 2). The co-expression of EpCAM+CD44+, EpCAM
+CD24+, and EpCAM+ABCG2+ ranged from 0.83% to 42.6%,
0.65% to 41.4%, and 1.6% to 6.5%, respectively, in the eight
RB  tumor  samples  (Figure  3,Figure  4,Figure  5,Figure
6,Figure 7,Figure 8,Figure 9, and Figure 10). The percentage
of cancer cells expressing a single surface marker in individual
tumors was significantly different. Except tumor No.1, all
other tumors showed a significantly higher percentage of cells
positive  for  the  combination  markers.  The  percentage  of
Figure  13.  Comparison  of  cell
proliferation kinetics between epithelial
cell adhesion molecule (EpCAM)+ and
EpCAM-  populations.  The  methyl
thiazol tetrazolium (MTT) assay graph
shows higher cell proliferation rate in
EpCAM+ population compared to that
of  EpCAM-  population.  The  viability
was determined in both populations at
day  2,  6,  10  and  14.  Statistically
significant increased in cell viability of
EpCAM+  population  was  observed  at
6th, 10th and 14th day. Asterisk mark
represent  p  value  less  than  0.05  as
analyzed  by  t-test  and  the  error  bars
represent standard error mean obtained
from triplicate values.
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300ABCG2 was less in all eight tumors, which is consistent with
a previous study [31]. Although the expression of AGCB2 was
less in tumors, we could still see that a small subpopulation of
ABCG2-positive cells co-expressed EpCAM.
Isolation and characterization of EpCAM+ cells in the Y79
cell line: Next, we demonstrated that EpCAM+ cells possess
cancer stem cell-like properties. We successfully enriched
EpCAM+ and EpCAMˉ populations from Y79 cells by using
a magnetic cell sorting technique; this produced 90% purity
in EpCAM+ cells and 90% purity in EpCAMˉ cells 1 day after
sorting (Figure 11).
Figure 14. Comparison of invasion property between epithelial cell adhesion molecule (EpCAM)+ and EpCAM- cells. A: Representative
microscopy picture showing the invasion of EpCAM– Y79 cells. B: Representative microscopy picture showing the invasion of EpCAM+ Y79
cells. C: Bar diagram showing increased number of EpCAM+ cells (bar 2) invading the matrigel compared to EpCAM– cells (bar 1). Smilarly,
bar 4 shows decrease in the invasion of EpCAM+ cells treated with EpCAM specific small interfering RNA when compared to small interfering
RNA (siRNA) untreated EpCAM+ cells (bar 3). The error bars represent standard error mean of triplicate values. For statistical analysis, group
2 was compared with group 1 and group 4 was compared to group 3. Asterisk mark represent p value less than 0.05 which is statistically
significant as analyzed by t-test.
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301Differentiation  potential  of  EpCAM+  cells:  In  the
differentiation assay the initially sorted EpCAM+ (81%) RB
population  ultimately  decreased  in  time  to  33.7%  of  the
EpCAM+  fraction  after  14  days  of  culture  (Figure  12).
However, a small percentage of EpCAM+ fractions remained
stable in sorted EpCAMˉ RB cells even after 14 days of culture
(Figure 12).
Proliferation and invasion potential of EpCAM+ Y79 cells:
Having isolated the EpCAM+ cells from Y79 cells, we next
determined their cancer stem-like cell properties. EpCAM+
cells had a higher proliferation rate than EpCAMˉ cells, as
assessed by the MTT assay (p<0.05, Figure 13) and were more
invasive in in vitro matrigel Transwell invasion assays when
compared to EpCAMˉ cells (p<0.05; Figure 14B). Similarly,
when EpCAM+ cells were treated with EpCAM– siRNA in
Figure 15. Comparison of neurosphere forming potential between epithelial cell adhesion molecule (EpCAM)+ and EpCAM- cells. A: Phase
contrast microscope image showing the formation of neurospheres by EpCAM– cells in the cell culture plates. B: Phase contrast microscope
image showing increased number of neurospheres by EpCAM+ cells in the cell culture plates. C: Bar diagram showing the number of colonies
formed by EpCAM+ cells and EpCAM- cells. Red bars indicate number of neurosphere clusters formed by EpCAM+ cells whereas blue bars
indicate the number of neurosphere clusters formed by EpCAM- cells. Asterisk mark over red bars indicate statistically significant (p<0.05)
increase in number of neurospheres as analyzed by t-test. Black bars indicate decrease in number of neurospheres by EpCAM+ cells after
siRNA treatment. Grey bars indicate number of neurospheres formed by small interfering RNA (siRNA) untreated EpCAM+ cells (control
cells–CTRL). Asterisk mark over black bar indicates statistically significant (p<0.05) decrease in number of neurospheres as analyzed by t-
test. The error bars represent standard error mean of triplicate values.
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302vitro  for  48  h,  the  invasive  potential  was  decreased
significantly  (p<0.05;  Figure  14B)  compared  to  siRNA
untransfected EpCAM+ cells.
Neurosphere formation potential of EpCAM+ Y79 cells: We
examined EpCAM+/EpCAMˉ Y79 cells for their capacity to
form  neurospheres,  an  indicator  of  stem  cell  self-renewal
[33].  The  isolated  EpCAM+  cells  formed  neurospheres
efficiently, while EpCAM– cells failed to do so (Figure 15A).
After  5  days,  neurospheres  were  counted  and  results
presented,  as  shown  in  Figure  15B.  Furthermore,
neurospheres could be repeatedly passaged. It appears that
EpCAM+  cells  but  not  EpCAM−  cells  have  self-renewal
capabilities with the ability to form colonies from a single cell.
To confirm the findings, EpCAM+-sorted cells were treated
with EpCAM– siRNA in vitro for 48 h, and we observed that
the number of neurospheres decreased significantly (p<0.05;
Figure  15B)  compared  to  siRNA  untransfected  EpCAM+
cells.
Higher β-catenin expression in EpCAM+ cells: The isolated
EpCAM+  cells  showed  increased  β-catenin  expression
compared  to  EpCAMˉ  cells  (Figure  16),  indicating  that
EpCAM might be involved in the β-catenin-mediated self-
renewal ability of tumor cells.
Effect of EpCAM×CD3 against human retinoblastoma cells:
The in vitro efficacy of EpCAM×CD3 antibody was tested in
a FACS-based cytotoxicity assay using CD3-positive pre-
activated  PBMCs  of  healthy  donors  as  effector  cells  and
EpCAM-positive human RB cells as target cells (tumor 1).
There was a strong dose-dependent effect of EpCAM×CD3
on RB cells over a 24-h time period (Figure 17A). We did not
observe significant tumor cell lysis after 2 h of incubation in
the presence of EpCAM×CD3. However, tumor cell lysis
occurred after 8 h of incubation but remained low with 17%
lysis above background levels. Following 16 h of incubation,
maximal specific lysis reached 59% and EC50 was reached at
an  EpCAM×CD3  concentration  of  20  ng/ml.  A  24-h
incubation  resulted  in  71%  specific  lysis  at  1  µg/ml
EpCAM×CD3 with an EC50 value of 2 ng/ml.
To validate the results and test for reproducibility, we
tested  the  efficacy  of  EpCAM×CD3  on  four  more  tumor
samples that were positive for EpCAM. Overall, we observed
a mean tumor cell death of 68.4% out of the five tumors,
ranging from 61% to 72% cell death (Figure 17B).
Secretion of cytokines IFN-γ, TNF-α, and interleukins by pre-
activated lymphocytes in the culture medium: After 72 h of
incubation, we observed increased levels of IFN-γ, TNF-α,
IL-10, IL-2, and TGF-β1 in the supernatant of RB tumor cell
and PBMC cultures incubated with 1 µg/ml of EpCAM×CD3
antibody compared to an incubation with CD3 or EpCAM
monoclonal antibodies alone (Figure 18). There was also a
significant  increase  in  perforin  levels  with  EpCAM×CD3
after 72 h of incubation compared with control antibodies
(Figure 18E).
DISCUSSION
EpCAM has not been associated with any of the cancer stem
cell markers in retinoblastoma. Using flow cytometry, we
studied the individual expression of EpCAM, CD44, CD24
Figure  16.  Western  blotting  analysis
demonstrating  the  levels  of  epithelial
cell adhesion molecule (EpCAM) and
β-catenin  levels  in  EpCAM+  and
EpCAM- cells. Panel 1 shows decreased
levels  of  β-catenin  in  EpCAM-  cells
compared  to  that  of  EpCAM+  cells.
Panel 2 shows decreased EpCAM levels
in EpCAM- cells compared to EpCAM
+ cells. Panel 3 shows equal expression
of  β-actin  (loading  controls)  in  both
EpCAM+  and  EpCAM-  cells.  kDa
stands for kilo-dalton.
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303and ABCG2 and also studied the co-expression of EpCAM
with other three putative cancer stem cell markers. All the
markers expressed at different levels in 8 tumor samples. We
observed that a subpopulation of tumor cells in all the samples
showed dual expression of EpCAM with CD44, CD24 and
ABCG2 individually (Figure 1). Thus, the present data clearly
showed that EpCAM is co-expressed with three other cancer
stem-like cell markers. Previous studies have shown CD44 to
be the hallmark of cancer stem cells in leukemia, pancreatic,
and  breast  cancers  [34-39].  The  expression  of  CD44  in
primary RB tumors could be due to the presence of hyaluronic
acid in the vitreous fluid [31].
EpCAM-positive cells isolated from the Y79 cell line
demonstrated  a  self-renewal  capability  by  forming  a
Figure  17.  Varying  concentrations  of
epithelial  cell  adhesion  molecule
(EpCAM)xcluster  determinant  (CD)3
antibody  inducing  cytotoxicity  on
retinoblastoma  (RB)  tumor  cells.  A:
Graph  shows  the  effect  of  increasing
serial  10-fold  concentrations  of
EpCAMxCD3 on the cytotoxicity of RB
tumor  cells  at  different  incubation
periods.  The  error  bars  represent
standard error mean of triplicate values.
Asterisk  mark  represent  statistically
significant  (p<0.05;  analyzed  by
Analysis of Variance method) increase
in cytotoxicity of RB tumor cells at 16 h
and 24 h incubation periods compared
to that of 2 h and 8 h incubation periods.
B: Effect of varying concentrations of
EpCAMxCD3 on five RB tumors. The
graph  shows  the  cytotoxic  effects  of
various  concentrations  of
EpCAM×CD3  antibody  on  five  RB
primary tumors after 24 h of incubation.
The error bars represent standard error
mean  of  triplicate  values.  The  table
under  the  graph  represents  the
percentage  cytotoxicity  of  each  RB
tumor  at  particular  concentration  of
EpCAMxCD3 antibody.
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304significantly higher number of neurospsheres in vitro and
showing increased invasion potential in the matrigel in vitro.
These results suggest that EpCAM expression might play a
significant role in promoting the neurospheres formation and
EpCAM may be associated with RB tumor invasion property .
To a large extent, EpCAM+ cells turned to EpCAM– cells,
which  indicate  that  EpCAM+  cells  demonstrate  a
differentiation  potential,  a  characteristic  feature  of  cancer
Figure 18. Production of cytokines by T-cells in the culture supernatant containing retinoblastoma (RB) tumor cells incubated with or without
epithelial cell adhesion molecule (EpCAM)xcluster determinant (CD)3 antibody. A: Bar diagram shows statistically significant (*p<0.05; by
t-test) increase in the levels of interferon-gamma (INF-γ) in the culture supernatant incubated with EpCAMxCD3 (Epithelial cell adhesion
molecule X cluster determinant-3) antibody compared to that of EpCAM antibody. B: Bar diagram shows statistically significant (*p<0.05;
by t-test) increase in the levels of tumor necrosis factor alpha (TNF-α) in the culture supernatant incubated with EpCAMxCD3 antibody
compared to that of EpCAM antibody. C: Bar diagram shows statistically significant (*p<0.05; by t-test) increase in the levels of interleukin-10
(IL-10) in the culture supernatant incubated with EpCAMxCD3 antibody compared to that of EpCAM antibody. D: Bar diagram shows increase
in the levels of transforming growth factor-β1 (TGF-β1) in the culture supernatant incubated with EpCAMxCD3 antibody compared to that
of EpCAM antibody. E: Bar diagram shows statistically significant (*p<0.05; by t-test) increase in the levels of interleukin-2 (IL-2) in the
culture supernatant incubated with EpCAMxCD3 antibody compared to that of EpCAM antibody. F: Bar diagram shows statistically significant
(*p<0.05; by t-test) increase in the levels of perforin in the culture supernatant incubated with EpCAMxCD3 antibody compared to that of
EpCAM antibody. Error bars in the entire bar diagrams represent standard error mean of triplicate values.
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305stem cells. Thus, it is clear that EpCAM+ Y79 cells behave
like cancer stem cells. This was further evidenced by the
presence of increased expression β-catenin, a critical player
for maintaining embryonic stem cells [39], in the isolated
EpCAM+ Y79 cells compared to EpCAM¯ cells. Increased
β-catenin levels are produced in cells due to the activation of
canonical Wingless and Int1 (Wnt) pathway activation [40].
The Wnt signaling pathway is implicated in the self-renewal
and differentiation of stem cells [39]. A controversial study
was published by Shoshana et al. [41] that reported the Wnt
signaling  pathway  has  tumor  suppressor  properties  in  the
retinoblastoma cell line. However, a recent study by Amanda
et al. [10] demonstrated that the GSK-3 β inhibitor lithium
chloride activates Wnt signaling in retinoblastoma Y79 and
WERI cell lines. While the ambiguity in these two different
controversial data sets needs to be addressed, one possible
reason for the difference is the differences in the cell lines
used.
Our study shows for the first time that EpCAM+ RB cells
behave like cancer stem cells. However, further in vivo studies
need to be performed to confirm these findings. Therefore,
targeting  CSC  pools  together  with  conventional
chemotherapies should be an essential treatment strategy to
eradicate  a  tumor  mass  [42].  Both  EpCAM  and  CD3
molecules are attractive targets for the generation of bsAb and
bispecific  single-chain  antibody  constructs  for  anticancer
treatment [43-45].
We observed that pre-activated PBMC’s have effectively
caused  lysis  of  RB  tumor  cells  in  the  presence  of
EpCAM×CD3. This effect was consistently noticed in all 5
tumors  studied.  The  activity  of  EpCAM×CD3  was  dose-
dependent and increased over a 24-h time period. Our ELISA
assays  have  demonstrated  increase  in  effector  cytokines
production in the supernatants of culture containing EpCAM
+ cells and pre-activated PBMC’s along with EpCAM×CD3.
Taken together, our results are consistent with the study of
Salnikov et al. [46] in that EpCAM×CD3 potently stimulates
pre-activated lymphocytes to secrete effector cytokines in the
presence  of  EpCAM  expressing  tumor  cells.  Secretion  of
TNF-α, IFN-γ, and chemokines by activated T cells may add
to  a  therapeutic  effect  through  intensive  immune  cell
attraction and stimulation. High levels of IL-10 within the
tumor microenvironment have been shown to favor tumor
rejection by enhancing cytotoxicity of T lymphocytes [47].
On the other hand it has been shown that TGF-β has a tumor
cell inhibitory function [48], and our results in the present
study  suggest  that  the  bi-specific  antibody  mediated
immunotherapy approach might help control RB tumor cell
proliferation. A high proportion of cells in retinoblastoma
express  EpCAM,  and  tumors  with  optic  nerve/choroidal
invasion  in  particular  show  increased  EpCAM  expression
[14].  Therefore,  invasive  retinoblastoma  tumors  are
interesting  tumors  for  target  therapy  using  bispecific
antibodies (EpCAM×CD3). In conclusion, we showed that
EpCAM+ RB cells behave like cancer stem cells in vitro.
EpCAM×CD3 possesses potent antitumor activity in vitro by
inducing  secretion  of  interleukins  and  cytokines  by  pre-
activated lymphocytes in the presence of EpCAM-expressing
RB tumor cells.
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